Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy
Zinal Chheda(University of California, San Francisco), Hideho Okada(University of California, San Francisco)
Cited by 215
Related Papers
Induction of CD8<sup>+</sup>T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma
|Journal of Clinical Oncology|2010|561
Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas
|Journal of Clinical Investigation|2017|411
Inhibition of STAT3 Promotes the Efficacy of Adoptive Transfer Therapy Using Type-1 CTLs by Modulation of the Immunological Microenvironment in a Murine Intracranial Glioma
|The Journal of Immunology|2008|104
Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment
|JCI Insight|2024|39
Glioma-neuronal circuit remodeling induces regional immunosuppression
|bioRxiv (Cold Spring Harbor Laboratory)|2023|7